Bröer Sonja, Löscher Wolfgang
Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine, 30559 Hannover, Germany; Center for Systems Neuroscience, 30559 Hannover, Germany.
Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine, 30559 Hannover, Germany; Center for Systems Neuroscience, 30559 Hannover, Germany.
Epilepsy Behav. 2015 Dec;53:98-107. doi: 10.1016/j.yebeh.2015.09.028. Epub 2015 Nov 2.
The discovery and validation of biomarkers in neurological and neurodegenerative diseases is an important challenge for early diagnosis of disease and for the development of therapeutics. Epilepsy is often a consequence of brain insults such as traumatic brain injury or stroke, but as yet no biomarker exists to predict the development of epilepsy in patients at risk. Given the complexity of epilepsy, it is unlikely that a single biomarker is sufficient for this purpose, but a combinatorial approach may be needed to overcome the challenge of individual variability and disease heterogeneity. The goal of the present prospective study in the lithium-pilocarpine model of epilepsy in rats was to determine the discriminative utility of combinations of phenotypic biomarkers by examining their ability to predict epilepsy. For this purpose, we used a recent model refinement that allows comparing rats that will or will not develop spontaneous recurrent seizures (SRS) after pilocarpine-induced status epilepticus (SE). Potential biomarkers included in our study were seizure threshold and seizure severity in response to timed i.v. infusion of pentylenetetrazole (PTZ) and behavioral alterations determined by a battery of tests during the three weeks following SE. Three months after SE, video/EEG monitoring was used to determine which rats had developed SRS. To determine whether a biomarker or combination of biomarkers performed better than chance at predicting epilepsy after SE, derived data underwent receiver operating characteristic (ROC) curve analyses. When comparing rats with and without SRS and sham controls, the best intergroup discrimination was obtained by combining all measurements, resulting in a ROC area under curve (AUC) of 0.9592 (P<0.01), indicating an almost perfect discrimination or accuracy to predict development of SRS. These data indicate that a combinatorial biomarker approach may overcome the challenge of individual variability in the prediction of epilepsy.
在神经和神经退行性疾病中发现和验证生物标志物,对于疾病的早期诊断和治疗方法的开发而言是一项重大挑战。癫痫通常是脑损伤(如创伤性脑损伤或中风)的后果,但目前尚无生物标志物可用于预测有风险的患者是否会发生癫痫。鉴于癫痫的复杂性,单一生物标志物不太可能足以实现这一目的,可能需要采用组合方法来克服个体变异性和疾病异质性的挑战。本项关于大鼠癫痫锂 - 匹罗卡品模型的前瞻性研究的目标,是通过检查其预测癫痫的能力来确定表型生物标志物组合的判别效用。为此,我们采用了一种近期改进的模型,该模型能够比较匹罗卡品诱导的癫痫持续状态(SE)后是否会发生自发性反复癫痫发作(SRS)的大鼠。我们研究中纳入的潜在生物标志物包括对定时静脉输注戊四氮(PTZ)的癫痫阈值和癫痫严重程度,以及在SE后的三周内通过一系列测试确定的行为改变。SE三个月后,使用视频/脑电图监测来确定哪些大鼠发生了SRS。为了确定生物标志物或生物标志物组合在预测SE后癫痫方面是否比随机猜测表现更好,对所得数据进行了受试者操作特征(ROC)曲线分析。在比较有和没有SRS的大鼠以及假手术对照组时,通过组合所有测量值获得了最佳的组间判别,曲线下面积(AUC)为0.9592(P<0.01),表明在预测SRS发生方面几乎具有完美的判别能力或准确性。这些数据表明,组合生物标志物方法可能会克服癫痫预测中个体变异性的挑战。